[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"candida-auris-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:candida-auris-infection":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100612417","evaluation-of-rapid-diagnostic-device-for-the-detection-of-candida-auris-100612417",false,"NCT07253311","Evaluation of Rapid Diagnostic Device for the Detection of Candida Auris","Evaluation of Rapid Diagnostic Device for the Detection of Candida Auris DiagRaMIE C AURIS","DiagRaMIE Caur","Inclusion Criteria:\n\nFrom patients with suspected Candida auris infection:\n\n\\- All isolates from the population that grow on the selective media: Sabouraud-dextrose (40g\u002FL dextrose, 5.0g\u002FL of peptic digest of animal tissue, 5.0 g\u002FL of pancreatic digest of casein, 15.0 g\u002FL of agar and final pH 5.6 ± 0.2) and CHROMagar™ Candida plus (manufactured by CHROMagar™, France). used in the hospital's routine diagnostic process.\n\nFrom patients with suspected Candida auris cutaneous colonization:\n\n\\- All isolates from the population that grow on the selective media: Salt-Sabouraud Dulcitol Broth (SSDB) with chloramphenicol and gentamicin (manufactured by S2 Media, United States), And the media used in the hospital's routine diagnostic process: Sabouraud Dextrose Liquid Medium containing NaCl 10%, chloramphenicol 50 mg\u002FL.\n\nExclusion Criteria:\n\n* NA","ALL","18 Years",{"count":20,"type":21},554,"ESTIMATED","OBSERVATIONAL","\"Candida auris is an emerging fungus that can cause severe infections, particularly in hospitalized patients, and is often resistant to multiple antifungal treatments. Rapid and accurate detection of this pathogen is essential to control its spread in healthcare settings.\n\nThis study aims to evaluate the clinical performance of the NG-Test® Candida auris rapid diagnostic test (RDT), developed by CEA and NG Biotech. The test uses immunochromatography and can detect Candida auris in about 15 minutes. Its results will be compared to the reference method, MALDI-TOF, performed on colonies grown from routine patient samples.\n\nBoth retrospective (using stored isolates) and prospective (using new isolates) evaluations will be conducted. The study will measure the sensitivity and specificity of the test, and also include an assessment of its ease of use by laboratory staff. No additional samples will be collected from patients, and all testing will use de-identified isolates to ensure confidentiality.\"",[25,26,27],"Candida Auris Infection","Candida Auris Colonization","Nosocomial Infections",[29,30,31,32,33,34,35,36,37],"Candida auris","Diagnostic Tests","Routine","Immunochromatography","Microbiological Techniques","Sensitivity and Specificity","Microbial Drug Resistance, Fungal","Infection","Control","RECRUITING","2026-06-22",{"date":41,"type":42},"2026-06-24","ACTUAL",{"date":44,"type":42},"2026-05-25",{"date":46,"type":21},"2026-10-31",{"name":48,"class":49},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100537798","phase-4-nasal-antisepsis-for-c-auris-prevention-100537798","NCT06282510","Nasal Antisepsis for C. Auris Prevention","Impact of Nasal Antisepsis on Candida Auris Colonization","Inclusion Criteria:\n\n* History of C. auris colonization or infection\n* Patient in a participating facility\n\nExclusion Criteria:\n\n* History of severe allergy to iodine-based products, defined as anaphylaxis or rash\n* Currently breastfeeding or pregnant\n* Non-English language speaking",{"count":59,"type":21},120,"INTERVENTIONAL",[62],"PHASE4","This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.",[25,65],"Colonization, Asymptomatic",[29,67,68,69,70,71],"Decolonization","Colonization","Infection Prevention","Povidone Iodine","Long-term Care","2025-10-13",{"date":74,"type":42},"2025-10-15",{"date":76,"type":42},"2024-01-29",{"date":78,"type":21},"2028-12",{"name":80,"class":49},"Mary K Hayden",3]